Abstract
Mutation of FMR1 results in fragile X mental retardation1. The most common FMR1 mutation is expansion of a CGG repeat tract at the 5´ end of FMR1 (refs 2, 3, 4), which leads to cytosine methylation and transcriptional silencing5,6. Both DNA methylation and histone deacetylation have been associated with transcriptional inactivity7,8,9. The finding that the methyl cytosine-binding protein MeCP2 binds to histone deacetylases and represses transcription in vivo10,11 supports a model in which MeCP2 recruits histone deacetylases to methylated DNA, resulting in histone deacetylation, chromatin condensation and transcriptional silencing12. Here we demonstrate that the 5´ end of FMR1 is associated with acetylated histones H3 and H4 in cells from normal individuals, but acetylation is reduced in cells from fragile X patients. Treatment of fragile X cells with 5-aza-2´-deoxycytidine (5-aza-dC) resulted in reassociation of acetylated histones H3 and H4 with FMR1 and transcriptional reactivation, whereas treatment with trichostatin A (TSA) led to almost complete acetylated histone H4 and little acetylated histone H3 reassociation with FMR1, as well as no detectable transcription. Our results represent the first description of loss of histone acetylation at a specific locus in human disease, and advance understanding of the mechanism of FMR1 transcriptional silencing.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Imbert, G., Feng, Y., Nelson, D., Warren, S.T. & Mandel, J.-L. in Genetic Instabilities and Hereditary Neurological Disorders (eds Wells, R.D. & Warren, S.T.) 27– 53 (Academic Press, San Diego, 1998).
Verkerk, A.J. et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting a length variation in fragile X syndrome. Cell 65, 905– 914 (1991).
Rousseau, F. et al. Direct diagnosis of fragile X syndrome of mental retardation. N. Engl. J. Med. 325, 1673– 1681 (1991).
Yu, S. et al. Fragile X genotype characterized by an unstable repeat region of DNA. Science 252, 1179– 1181 (1991).
Sutcliffe, J.S. et al. DNA methylation represses FMR1 transcription in fragile X syndrome. Hum. Mol. Genet. 1, 397– 400 (1992).
Pieretti, M. et al. Absence of expression of the FMR1 gene in fragile X syndrome. Cell 66, 817– 822 (1991).
Razin, A. & Riggs, A.D. DNA methylation and gene function. Science 210, 604–610 (1980).
Allfrey, V.G., Faulkner, R. & Mirsky, A.E. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc. Natl Acad. Sci. USA 51, 786–794 ( 1964).
Turner, B.M. Decoding the nucleosome. Cell 75, 5– 8 (1993).
Nan, X. et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393, 386–389 (1998).
Jones, P.L. et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nature Genet. 19, 187– 191 (1998).
Razin, A. CpG methylation, chromatin structure and gene silencing—a three way connection. EMBO J. 17, 4905– 4908 (1998).
Braunstein, M., Rose, A.B., Holmes, S.G., Allis, C.D. & Broach, J.R. Transcriptional silencing in yeast is associated with reduced nucleosome acetylation. Genes Dev. 7, 592–604 (1993).
Chen, E.Y. et al. Sequence of human glucose-6-phosphate dehydrogenase cloned in plasmids and a yeast artificial chromosome. Genomics 10, 792–780 (1991).
Sasaki, T., Hansen, R.S. & Gartler, S.M. Hemimethylation and hypersensitivity are early events in transcriptional reactivation of human inactive X-linked genes in a hamster X human somatic cell hybrid. Mol. Cell. Biol. 12, 3819–3826 (1992).
Ammerpohl, O., Schmitz, A., Steinmuller, L. & Renkawitz, R. Repression of the mouse M-lysozyme gene involves both hindrance of enhancer factor binding to the methylated enhancer and histone deacetylation. Nucleic Acids Res.. 26, 5256–5260 (1998).
Chiurazzi, P., Pomponi, M.G., Willemsen, R., Oostra, B.A. & Neri, G. In vitro reactivation of the FMR1 gene involved in fragile X syndrome. Hum. Mol. Genet. 7, 109–113 ( 1998).
Van Lint, C., Emiliani, S. & Verdin, E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr. 5, 245–253 ( 1996).
Arts, J., Lansink, M., Grimbergen, J., Toet, K.H. & Kooistra, T. Stimulation of tissue-type plasminogen activator gene expression by sodium butyrate and trichostatin A in human endothelial cells involves histone acetylation. Biochem. J. 310 , 171–176 (1995).
Van Lint, C., Emiliani, S., Ott, M. & Verdin, E. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J. 15, 1112– 1120 (1996).
Rundlett, S.E. et al. HDA1 and RPD3 are members of distinct yeast histone deacetylase complexes that regulate silencing and transcription. Proc. Natl Acad. Sci. USA 93, 14503–14058 (1996).
Eberhart, D.E. & Warren, S.T. Nuclease sensitivity of permeabilized cells confirms altered chromatin conformation at the fragile X locus. Somat. Cell Mol. Genet. 22, 435 –441 (1996).
Drouin, R. et al. Structural and functional characterization of the human FMR1 promoter reveals similarities with the hnRNP-A2 promoter region. Hum. Mol. Genet. 6, 2051– 2060 (1997).
Schwemmle, S. et al. Characterization of FMR1 promoter elements by in vivo-footprinting analysis. Am. J. Hum. Genet. 60, 1354–1362 (1997).
Madisen, L., Krumm, A., Hebbes, T. & Groudine, M. The immunoglobulin heavy chain locus control region increases histone acetylation along linked c-myc genes. Mol. Cell. Biol. 18, 6281 –6292 (1998).
Luo, R., Postigo, A. & Dean, D. Rb interacts with histone deacetylase to repress transcription. Cell 92, 463–473 (1998).
Cameron, E. et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nature Genet. 21, 103–107 ( 1999).
Feng, Y. et al. Translational suppression by trinucleotide repeat expansion at FMR1. Science 268, 731– 734 (1995).
Lin, R., Leone, J., Cook, R. & Allis, C.D. Antibodies specific to acetylated histones document the existence of deposition- and transcription-related histone acetylation in Tetrahymena. J. Cell Biol. 108, 1577–1588 (1989).
Hendzel, M. et al. Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 106, 348–360 ( 1997).
Acknowledgements
We thank C.D. Allis for anti-phospho-H3 antisera and helpful discussions and T. Bestor, G. MacGregor, J. Boss, J. Lucchesi, P. Vertino and X. Cheng for helpful discussions. S.T.W. is an investigator of the Howard Hughes Medical Institute. This work was supported in part by NIH grant HD35576.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Coffee, B., Zhang, F., Warren, S. et al. Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells. Nat Genet 22, 98–101 (1999). https://doi.org/10.1038/8807
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/8807
This article is cited by
-
Unraveling the functional role of DNA demethylation at specific promoters by targeted steric blockage of DNA methyltransferase with CRISPR/dCas9
Nature Communications (2021)
-
Incomplete silencing of full mutation alleles in males with fragile X syndrome is associated with autistic features
Molecular Autism (2019)
-
Neuroepigenetic mechanisms in disease
Epigenetics & Chromatin (2017)
-
Protein sequestration as a normal function of long noncoding RNAs and a pathogenic mechanism of RNAs containing nucleotide repeat expansions
Human Genetics (2017)
-
Recent advances in assays for the fragile X-related disorders
Human Genetics (2017)